Douglas Williams turned heads in July when Biogen revealed that its executive vice president leading research and development was leaving to found a biotechnology startup, and now Williams has emerged from the fundraising process as the president and CEO of Codiak BioSciences with venture capital to develop exosomes-based therapeutics and diagnostics.
Douglas Williams turned heads in July when Biogen revealed that its executive vice president leading research and development was leaving to found a biotechnology startup, and now Williams has emerged from the fundraising process as the president and CEO of Codiak BioSciences with venture capital to develop exosomes-based therapeutics and diagnostics.
Codiak has a handful of employees – including a CEO with experience at both early-stage and big league biotechs firms...
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.
The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
